Subclinical hyperthyroidism not a risk factor for MACE in PCI patients

Subclinical hyperthyroidism (SHyper) does not independently correlate with major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), results of a study have shown.

A group of researchers conducted this study to explore the relationship between SHyper and adverse cardiovascular events in CAD patients who went through drug-eluting stent implantation. They consecutively recruited a total of 8,283 participants and divided them into two groups based on their thyroid functions: euthyroidism group (n=7,942) and SHyper group (n=341).

After propensity score matching, 1,603 patients (332 in the SHyper group and 1,271 in the euthyroidism group) were included in the analysis. MACE, a composite of cardiac mortality, nonfatal myocardial infarction (MI), and target vessel revascularization (TVR), was the primary endpoint.

On Kaplan‒Meier survival analysis, no significant between-group difference was observed in the primary endpoints (MACE: 11.4 percent vs 8.8 percent; log-rank p=0.124; cardiac death: 1.2 percent vs 0.9 percent; log-rank p=0.540; nonfatal MI: 5.7 percent vs 4 percent; log-rank p=0.177; and TVR: 6 percent vs 4.7 percent; log-rank p=0.303).

Cox regression analysis confirmed that SHyper was not independently predictive of MACE (hazard ratio, 1.33, 95 percent confidence interval, 0.92‒1.92; p=127).

“More studies should be implemented in the future to assess the long-term predictive value of SHyper with thyrotropin levels <0.1 mIU/L for CAD patients undergoing PCI,” the researchers said.